The US Food and Drug Administration approved the type 2 diabetes drug tirzepatide for use in chronic weight management Wednesday, making official the use of a medicine already widely prescribed off-label for weight loss.
The US Food and Drug Administration approved the type 2 diabetes drug tirzepatide for use in chronic weight management Wednesday, making official the use of a medicine already widely prescribed off-label for weight loss.
The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes semaglutide, known as Ozempic for diabetes and Wegovy for weight loss, which have skyrocketed in popularity in recent years.
Production is already online at one of the two factories in Durham, where Eli Lilly has a manufacturing site.
